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Abstract: Colorectal cancer (CRC) is the second cause of death in men and the third in women.
This work deals with the study of the low molecular weight protein fraction of sera from patients who
underwent surgery for CRC and who were followed for several years thereafter. MALDI-TOF MS
was used to identify serum peptidome profiles of healthy controls, non-metastatic CRC patients and
metastatic CRC patients. A multiple regression model was applied to signals preliminarily selected by
SAM analysis to take into account the age and gender differences between the groups. We found that,
while a signal m/z 2021.08, corresponding to the C3f fragment of the complement system, appears
significantly increased only in serum from metastatic CRC patients, a m/z 1561.72 signal, identified
as a prothrombin fragment, has a significantly increased abundance in serum from non-metastatic
patients as well. The findings were also validated by a bootstrap resampling procedure. The present
results provide the basis for further studies on large cohorts of patients in order to confirm C3f and
prothrombin as potential serum biomarkers. Thus, new and non-invasive tests might be developed
to improve the classification of colorectal cancer.
Keywords: serum; prothrombin; complement; peptidome; mass spectrometry; colorectal cancer
Diagnostics 2020, 10, 1077; doi:10.3390/diagnostics10121077 www.mdpi.com/journal/diagnostics
Diagnostics 2020, 10, 1077 2 of 15
1. Introduction
Colorectal cancer (CRC) is one of the most common cancers in the world. Even if its death rate
has dropped due to the screening techniques, it is still the second cause of death in men and the third
in women [1]. Early detection of CRC remains a challenge and the identification of new molecular
signatures represents an important field of translational research. Indeed, patients who receive an early
diagnosis of CRC and quickly undergo surgery have a favourable five-year survival rate. However,
many CRC cases are diagnosed at a late stage with dramatic consequences on both therapy and survival
rates [2,3].
In recent years, several authors have described the study of the low molecular weight fraction of
human serum for diagnostic and/or prognostic purposes in several diseases, including cancer [4–6].
In fact, it has been proposed that the low molecular weight fraction of the serum proteome may be
correlated with physio-pathological events occurring in all districts of the organism [7,8]. The possibility
of evaluating changes in the serum composition associated to CRC onset and progression could be
imagined as a valid alternative to the invasive colorectal biopsy for the future.
Mass spectrometry (MS) is well suited for the detection of proteins or peptides that might not be
detectable with traditional techniques and that might represent a dynamic reflection of tissue function.
In 2012, Fan and co-workers identified a peptide signature containing two peaks, at m/z 741 and 7772,
able to distinguish the CRC patients from healthy controls [9]. Recently, Wang et al. described a study
on human serum peptidome for diagnostic purposes in colorectal cancer [10]. The authors proposed a
diagnostic panel based on five peptides able to discriminate CRC patients from healthy controls (peaks
at m/z 1895.3, 2020.9, 2080.7, 2656.8 and 3238.5). Three peaks, having m/z 1895.3, 2020.9 and 3238.5
were identified as the partial sequences of complement component 4 (C4), complement component 3
(C3) and fibrinogen alpha chain (FGA), respectively. However, to the best of our knowledge, there are
no studies describing a peptidomic signature able to distinguish between different stages of the disease.
In this study, we used SeraDeg [11] to select the serum samples that were sufficiently preserved
to be included into the experimental groups. After the selection, a comparative analysis has been
performed by significant analysis of microarrays (SAM) [12] in order to identify a peptidomic signature
able to distinguish between healthy controls, non-metastatic CRC patients and metastatic CRC patients.
2. Materials and Methods
Acetonitrile, methanol and water were LiChrosolv solvents obtained from Merck (Darmstadt,
Germany). Trifluoroacetic acid (TFA) and alpha-cyano-4-hydroxycinnamic acid (CHCA) were obtained
from Fluka (Sigma-Aldrich, St. Louis, MO, USA).
2.1. Patient Selection and Ethical Aspects
Blood samples from 180 patients with CRC and 70 healthy volunteers were obtained. Samples were
collected between 2012 and 2016, prior to surgery, and aliquots were stored at −80 ◦C until processing.
Moreover, as the duration of cryopreservation could potentially affect the protein profile, as it was
previously evidenced by us [13], cases and controls were also rigorously matched for the length of
cryopreservation period. The CRC serum samples from patients were prepared from blood specimens
collected before the start of any anticancer treatment. The samples were collected in the Basque
Biobank for Research following a strict and standardized protocol to ensure the appropriate processing
and storage that preserves a correct protein profile. Samples were obtained from peripheral blood.
Tubes were centrifuged at 2500 rpm for 20 min at room temperature and placed in 500 µL aliquots.
The assessment of metastatic and non-metastatic patients was based on the “Protocol for the
Examination of Resection Specimens From Patients With Primary Carcinoma of the Colon and Rectum”
of the College of American Pathologists (2020) [14].
All the experiments carried out in this study comply with the current Spanish and European
Union legal regulations. Samples and data from patients included in this study were provided by
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the Basque Biobank for Research—OEHUN (http://www.biobancovasco.org/). All patients at Basurto
University Hospital were informed about the potential use for research of their biological samples
and accepted this eventuality by signing a specific document approved by the Ethical and Scientific
Committees of the Basque Country Public Health System (Osakidetza) (CEIC 11-51).
2.2. Solid Phase Extraction
Functionalised super-paramagnetic beads (DynabeadsVR RPC 18 Life Technologies Dynal, Irvine,
CA, USA) with a C18 alkyl-modified surface were used to prepare a low molecular weight (LMW)
protein fraction from serum. Serum sample preparation was performed as described in detail in a
previous paper [15]. Some modifications were applied to the DynabeadsVR RPC 18 manufacturer’s
protocol. Briefly, 40 µL of the bead suspension were washed once with water and thrice with 100 µL of
200 mM NaCl, 0.1% TFA. The beads were re-suspended in 20 µL of water, mixed with 50 µL of serum
and incubated at room temperature for 5 min. After incubation, the tube was placed in a magnetic
concentrator (Dynal MPCVR, Invitrogen Dynal, Oslo, Norway), and the supernatant was discarded.
The bead-peptide complex was washed thrice with 300 µL of 0.1% TFA in water, and the bound
peptides were eluted by incubation at room temperature for 2 min with 12 µL of a 1:1 acetonitrile/water
solution containing 3.5 pmol/µL of a synthetic internal standard peptide (MW 1419.76). This standard
peptide, which was later used to normalize the data, was directly spiked in the eluting solution in
order to avoid any interference during the binding reaction between analytes and the magnetic beads.
2.3. API-MALDI/TOF MS Analysis
The target plates for the API-MALDI/TOF analysis were prepared following the standard procedure
previously cited [4]. Briefly, one volume of the eluted sample was mixed with two volumes of premade
matrix solution (6.2 mg of CHCA in 1 mL of 36% methanol, 56% acetonitrile and 8% water). Next, 1 µL
of this mixture was spotted in quadruplicate onto the MALDI target plate and allowed to dry at room
temperature in a vacuum desiccator. API-MALDI/TOF analysis was performed in positive mode on a
6210 Time of Flight LC/MS (Agilent, Santa Clara, CA, USA) coupled with an atmospheric pressure
PDF-MALDI Ion Source (Agilent) equipped with a 337 nm nitrogen laser. The following voltages were
applied: fragmentor 300 V, skimmer 60 V, OCT RF 300 V. The acquisition laser power was set at 35%
of maximum (peak power 75 kW, pulse energy 300 mJ). Data acquisition was automated using Mass
Hunter software (Agilent) and programmed to accumulate 600 shots per spectrum. The irradiation
program was automated using the spiral motion control of the PDF-MALDI ion source. The instrument
was externally calibrated using Tuning Mix (Agilent). The nominal resolution of the instrument was
20.000 (17.000 observed), and the nominal mass accuracy (with internal calibration) was <2 ppm.
2.4. Nano-LC Mass Spectrometry
An aliquot of the DynabeadsVR RPC 18 extracted peptides was analysed by nano-HPLC-MS/MS
using an Ultimate 3000 nano-HPLC system managed by the CHROMELEON Chromatography Data
System (CDS) software (Thermo Scientific, Oslo, Norway) connected to a Hybrid Quadrupole-Orbitrap
mass spectrometer (Q Exactive, Thermo Scientific).
The peptides were re-suspended immediately before analysis and were first loaded onto a trapping
column (Acclaim PepMap C18, length 20 mm, diameter 0.1 mm, particle size 5 µm, pore size 100 Å,
Thermo Fisher Scientific, Oslo, Norway) using the loading solvent (5–95% acetonitrile/water + 0.05%
trifluoroacetic acid) at a flow rate of 5 µL/min for 5 min. The trapping column was then switched
in-line with the separation column, and the peptides were eluted with increasing organic solvent at a
flow rate of 300 nL/min. Mobile phase A was 0.1% formic acid in water; mobile phase B was 95–5%
acetonitrile/water + 0.08% formic acid. The separations were carried out at 35 ◦C using an Easy spray
column (PepMap RSLC C18, length 150 mm, diameter 0.075 mm, particle size 3 µm, pore size 100 Å,
Thermo Scientific) applying a linear gradient from 4% to 95% of eluent B in 55 min.
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All the analyses were carried out in the positive ion mode in a mass range between 395 and
2000 m/z. Single MS survey scans were performed in the Orbitrap using a maximal ion injection time
of 100 ms. The resolution was set to 70,000, and the automatic gain control was set to 3 × 106 ions.
The experiments were performed in data-dependent acquisition mode with alternating MS and MS/MS
experiments. The minimum MS signal to obtain MS/MS was set to 500 ions, with the most prominent
ion signal selected for MS/MS using an isolation window of 2 Da. The m/z values of signals already
selected for MS/MS were put on an exclusion list for 5 s using dynamic exclusion. In all cases,
one micro-scan was recorded. Collision-induced dissociation (CID) was done with a target value of
5000 ions, a maximal ion injection time of 50 ms, normalized collision energy of 35%. A maximum of
10 MS/MS experiments/MS scan were performed.
Raw MS files were processed with the Thermo Scientific Proteome Discoverer software version
1.4. Peak list files were obtained by the SEQUEST search engine against the Homo Sapiens database
containing both forward and reversed protein sequences. The resulting peptide hits were filtered for a
maximum 1% FDR (false discovery rate) using the percolator tool. The peptide mass deviation was
set to 10 ppm, and a minimum of six amino acids to identify peptides were required. The database
search parameters were: mass tolerance precursor 20 ppm, mass tolerance fragment CID 0.8 Da with
dynamic modification of deamidation (N, Q), oxidation (M). For all searches, the option trypsin with
two missed cleavages was selected.
2.5. API-MALDI/TOF MS Data Format Conversion
Raw data generated by the Qualitative Analysis software (Agilent Technologies, Santa Clara, CA,
USA) were converted from the proprietary format (.d) to the mzML standard format by using MSconvert,
a tool of the software suite ProteoWizard [16]. Four spectra, corresponding to the quadruplicated spots,
were then determined for each sample by averaging 15 consecutive scans from the original data by
means of the MALDIquant R package [17].
2.6. Sample Selection
All serum samples were tested for their integrity by means of SeraDeg [11], a publicly available
web tool aimed to assess the quality of sera through a comparative analysis of the contents, in the
related MS spectra, of fibrinopeptide A (fpA) fragments, a molecule which is known to be easily
degraded under physico-chemical stress conditions. For each sample, SeraDeg provides quality scores
(SeraDeg quality score—SDQS) that allow researchers to assess the quality of samples and discard
those samples that do not have an adequate quality.
This score is mainly based on the overall abundance of fpA fragments, which is compared to the
overall abundance of the same molecules in a reference spectrum derived from a sample of assessed
quality and the ratio between the percentages of high-mass (m/z 1350.6 and 1465.63) and low-mass
(m/z 905.46 and 1077.53) fpA fragments.
The spectra created during the previous step by using MALDIquant were exported in text format
(two columns: one for the m/z value, one for the relative abundance) and included in a compressed
zip archive in order to analyse them with SeraDeg. The following thresholds were applied for the
selection: overall abundance of fpA fragments greater than 33.33% of the overall abundance in the
reference spectrum, percentage of high-mass fpA fragments greater than 66.67% of the percentage of
low-mass fpA fragments.
According to the results of this analysis, only a subset of the samples that were initially acquired
was finally used in the following statistical analysis.
2.7. Spectra Pre-Processing
Lists of peaks were determined for each spectrum by applying a two-step procedure. All peaks
were first determined by selecting local maxima (i.e., values in the given spectrum higher than both
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the previous and the following values). The final list of peaks was then determined by applying a
median filter (half window size of 20 and signal-to-noise ratio of 2.5).
The lists of peaks were then analysed by means of Geena 2, a publicly available web tool for
pre-processing MALDI/TOF spectra that, among other functions, is able to:
• Normalize both abundances and adjust m/z values against a reference signal;
• Sum up isotopic peaks of the same molecule;
• Average technical replicas from each sample, thus producing a single spectrum that is representative
for the sample;
• Align representative spectra and produce a table of aligned signals with corresponding abundances.
Both the average and alignment steps above allow discarding those signals that are included
only in a few spectra, so that sporadic signals can be removed from the output. For the average step,
we adopted a high threshold (at least three spectra out of the four replicas must include the signal for its
inclusion in the alignment). For the alignment step, instead, we had to define a low threshold in order
to prevent that signals present only in one of the groups under analysis were discarded. The smaller
group led this choice. We set this threshold to five: only signals found in at least five representative
spectra were included in the final alignment.
2.8. Statistical Analysis
The output generated by Geena 2 was then analysed by means of SAMR, in order to identify
signals significantly different in the groups, i.e., healthy volunteers, patients affected by metastatic
CRC and patients affected by non-metastatic CRC. The multiple regression model [18] was applied to
peptides eventually selected by the SAM analysis to take into account the age and gender differences
between the two groups of patients and controls. The parameters estimated by this model can be
interpreted as the difference in the mean values of a peptide between patients and controls. Given the
small size of our sample, we chose to obtain a robust estimate of the standard errors of the model
parameters by using a non-parametric bootstrap.
2.9. Data Validation
A bootstrap resampling procedure was implemented in order to validate the output of the SAM
analysis. The bootstrap method consists in the construction of new datasets by randomly resampling
from the original one [19]. Bootstrap may be implemented with or without replacement. In the
former case, the new datasets are created by selecting samples from the original data set without
any supervision and may, therefore, include any of the original samples more times. Additionally,
with replacement of the size of the new datasets may be equal or even greater than the size of the
original dataset, thus including more samples than originally. In the latter case, instead, any replication
is avoided, and the size of new datasets must strictly be lower than the original size.
Due to the relatively small number of samples involved in our analysis, we preferred to avoid
reducing the number of samples in the validation datasets, and we, therefore, applied bootstrap with
replacement. Moreover, we choose to keep the size of the new datasets identical to the size of the
original dataset, thus avoiding an excessively high number of duplicated samples in the datasets.
By bootstrapping with replacement from the original dataset, we thus created 100 new datasets
of the same size of the original one and executed the SAM analysis for each of them. The original
ratio between group sizes was also conserved. Finally, we evaluated the frequency of occurrence
of the peptides selected as significant by SAM on the original dataset in the results of the new
100 SAM analyses.
3. Results
In this study, we initially analysed the peptidomic profile of 250 serum samples (95 metastatic
CRC patients, 85 non-metastatic CRC patients and 70 healthy controls).
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3.1. API-MALDI/TOF MS Analysis
To determine the low-molecular-weight (LMW) protein profile spectra, the whole sample set was
analysed by API-MALDI/TOF mass spectrometry performed on the LMW fraction of sera. The good
quality of our MS spectra can be appreciated in Figure 1.
In order to avoid procedural biases, samples were randomly distributed during processing.
All spectra were acquired in quadruplicate in a mass range from 800 to 3000 m/z.
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Figure 1. Serum sample spectra. The figure includes two spectra: healthy control (A) and metastatic
colorectal cancer (CRC) patient (B). The intervals around the fragment at m/z 1561.725 have been
zoomed (i.s.: internal standard).
3.2. Selection of Samples
After the acquisition, the API-MALDI/TOF spectra were tested with SeraDeg in order to avoid
possible biases due to al ered preservation conditions. As previously reported, this operation selected
a set of samples of adequa quality and preservat on including 172 pathological samples, of which 92
patien s had been diagnosed with me astatic CRC, 80 patie ts had been di gn sed with non-metastatic
CRC, and 19 samples were from healthy volunteers (Table 1).
Table 1. Characteristics of the groups of patients taking part in the study.
Type Sample Size Gender Mean Age Age Range
Metastatic CRC 92 28F/64M 71 34–93
Non-Metastatic CRC 80 26F/54M 71 44–89
Healthy controls 19 10F/9M 54 40–67
CRC: colorectal cancer, F: female, M: male.
3.3. Selection of Candidate Signals
The sample set selected by SeraDeg was used as a discovery cohort to identify possible candidate
peptides able to distinguish controls from patients with reference to metastatic spreading. After the
pre-processing steps carried out by means of Geena 2 [20], a total of 122 peaks were detected.
Among these, 19 peaks were found to be related to fibrinopeptide A or B and were not considered in the
following analyses. Indeed, fpA fragments were used, as previously stated, by SeraDeg for the selection
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of less degraded samples and consequently taking them into account could erroneously drive the
final outcome. The number of useful signals was finally reduced to 103. The MS Excel files including
alignment data generated by Geena 2 as prepared for the SAM analysis for the comparison between
controls and non-metastatic samples and between controls and metastatic samples are included as
Supplementary Material Tables S1 and S2.
The significance of the SAM analysis was assessed by using the q-value that is similar to the
well-known p-value adapted to the situation where a large number of comparisons is carried out,
which is our case since we evaluated 103 peptides. The significance threshold for the q-value is
5%. When we compared the three groups of samples, the SAM analysis highlighted only three
signals (m/z 1561.72, 2021.08 and 2399.17) having a q-value of 5% or less either in the comparison
between controls and non-metastatic samples or between controls and metastatic samples (see Table 2).
No significant signals were found in the comparison between samples from non-metastatic and
metastatic patients.
Table 2. Results of significant analysis of microarrays (SAM) analysis on the original dataset.
Controls vs. Non Metastatic
Signal Controls (n = 19)Mean (SE)
Cases (n = 80)
Mean (SE) Score Fold Change q-Value
1561.720 0.22 (0.22) 3.67 (0.61) 2.371 16.408 *0.04490
2021.084 6.01 (2.12) 15.80 (2.54) 1.772 2.628 0.10264
2399.165 0.62 (0.45) 4.17 (0.79) 1.938 6.705 0.10264
Controls vs. Metastatic
Signal Controls (n = 19)Mean (SE)
Cases (n = 92)
Mean (SE) Score Fold Change q-Value
1561.720 0.22 (0.22) 3.97 (0.55) 2.634 17.786 * 0.03754
2021.084 6.01 (2.12) 17.52 (1.95) 2.489 2.915 * 0.03754
2399.165 0.62 (0.45) 4.28 (0.64) 2.246 6.877 * 0.03754
In the table, only those signals that were found significant in at least one of the analyses are reported. q-values are
highlighted by an asterisk * when significant. SE: standard error, n: number of cases.
Indeed, a signal at m/z 1051.71 was also highlighted by the SAM analysis as a significant signal
(q-value < 5%) in both comparisons, with a fold change of 2.5 for controls versus non metastatic samples
and of 2.7 for controls versus metastatic samples. However, this signal is known to be derived from
a polymer contaminant from either polypropylene or polyethylene plastic tubes [21]. Consequently,
it has been excluded from any further consideration.
Only one of the other signals, the one at m/z 1561.72, was significantly higher in non-metastatic
CRC patients when compared with healthy controls (fold change 16.4). When the healthy controls were
compared with the metastatic CRC patients, beyond the 1561.72 signal (whose fold change increased
to 17.8), the other two signals (at m/z 2021.08 and 2399.17, with fold change 2.9 and 6.9, respectively)
were also found significantly increased. These results are also represented in the form of dot plots in
Figures 2 and 3.
In Figure 2, the comparison between controls and non-metastatic patient is shown, while the
comparison of controls and metastatic patients is shown in Figure 3. For each of the three significant
signals, m/z 1561.72, 2021.08 and 2399.17, the abundance values of the signal in controls’ and patients’
spectra are shown separately.
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3.4. Identification of the Selected Serum Peptides by Nano-HPLC-ESI-MS/MS
In order to identify the origin of the selected candidate signals, a tandem mass spectrometry
experiment was performed a alysing a CRC serum sample that has one of the highest abundances
of these molecules. Following the submission of the data obtained by the LC separation and MS/MS
analysis to the SEQUEST search engine [22] against the Uniprot Homo Sapiens database, the amino acid
sequences of peptides m/z 1561.72 and m/z 2021.08 were, respectively, determined, with high confidence,
as belonging to prothrombin (Uniprot ID: P00734, sequence: “TATSEYQTFFNPR”) (Figure S1) and to
the fragment C3f of complement system C3 (Uniprot ID: P01024, sequence: “SSKITHRIHWESASLLR”)
(Figure S2), while the signal 2399.17 was identified as a double α-CHCA matrix adduct (with molecular
weight 189.04 Da) to the peptide at m/z 2021.08 (C3f). A signal at m/z 2210.13 corresponding to a single
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α-CHCA matrix adduct to the C3f peptide at m/z 2021.08 was also identified, but it was not considered
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controls, dots on the right (red) metastatic patients. The horizontal lines show the average values.
Dots are randomly spread along the abscise axis for visibility. Scales are adapted to values.
3.5. Validation by Bootstrap Resampling
As previously reported, bootstrap resampling with replacement was adopted in order to validate
the SAM analysis. Starting from the original dataset, we first created 100 new datasets of the same size,
and we then analysed them by using SAMR, an implementation of the SAM statistical test based on
the R language [23]. It is worth stressing that all results were congruent with the SAMR analysis, i.e.,
signals identified as increased between controls and non-metastatic patients were also found increased
at bootstrap, and vice versa. The same occurred when the analysis was applied to signals in the other
comparison, i.e., between controls and metastatic patients.
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In Table 3, the frequency by which each peptide identified as significant by the SAM analysis on
the original dataset was also identified as significant in the new datasets is reported. In this table,
the results of the bootstrap analysis are reported separately for the comparison between controls and
non-metastatic patients and between controls and metastatic patients. In both cases, the molecular
weight of the signal, the q-value of the SAMR analysis on the original data set and the number of
occurrences the signal has been considered significant (p < 0.05) in the repeated SAMR analyses on the
new datasets are reported.
Table 3. Results of the bootstrap analysis.
Controls vs. Non Metastatic Controls vs. Metastatic
Signal q-Value Bootstrap Signal q-Value Bootstrap
1561.720 * 0.04490 70/100 1561.720 * 0.03754 95/100
2021.084 0.10264 35/100 2021.084 * 0.03754 95/100
2399.165 0.10264 46/100 2399.165 * 0.03754 85/100
In this table, the results of the bootstrap analysis are reported in distinct sub-tables. Left: controls vs. non-metastatic
patients; right: controls vs. metastatic patients. In each table, the leftmost value is the molecular weight of the signal,
the central value is the q-value of the SAM analysis on the original data set, and the rightmost value is the number
of occurrences of the signal find as significant (p < 0.05) in the SAM analyses on the new datasets. * denote the
significant q-values (<0.05).
As expected, significant signals (p < 0.05) in the SAM analysis on the original dataset have a higher
number of occurrences. In particular, the signals of the greatest interest (m/z 1561.72 and m/z 2021.084)
have high/very high number of bootstrap occurrences, ranging from 70/100 for m/z 1561.72 in the
comparison between controls and non-metastatic patients to 95/100 for both signals in the comparison
between controls and metastatic patients.
Finally, Table 4 shows the results from the multiple regression models in order to validate the
findings of the SAM analysis taking into account the differences in age and gender between patients
and controls. Actually, the increases in abundance observed among patients compared to controls for
the selected peptides are confirmed.
Table 4. Results from applying the multiple regression model to the peptides selected by the SAM
analysis, adjusting by age and gender.
Adjusted by Age








1561.720 2.58 0.13–5.02 0.039 4.85 2.68–7.03 <0.001
2021.084 Untested because not significant by SAM 9.51 1.12–17.91 0.026
2399.165 Untested because not significant by SAM 3.54 0.65–6.43 0.016
Adjusted by Gender








1561.720 3.40 2.04–4.77 <0.001 3.75 2.55–4.95 <0.001
2021.084 Untested because not significant by SAM 10.84 5.57–16.11 <0.001
2399.165 Untested because not significant by SAM 3.33 1.86–4.81 <0.001
Signals at m/z 2021.084 and m/z 2399.165 were not tested for non-metastatic vs. controls comparison, because they
were not found significant by SAM analysis.
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4. Discussion
This study aimed at the construction of a serum peptide signature able to differentiate the three
evaluated populations (metastatic CRC patients, non-metastatic CRC patients and healthy volunteers).
The results of the SAM analysis on mass spectrometry data put in evidence three signals showing statistically
significant differences, which were able to distinguish between healthy volunteers and CRC patients.
This peptide signature includes the m/z 1561.72 (human pro-thrombin P00734, fragment
“TATSEYQTFFNPR”), m/z 2021.08 (C3 complement P01024, C3f complement fragment
“SSKITHRIHWESASLLR”) and m/z 2399.17, identified as a double α-CHCA matrix adduct to the
peptide at m/z 2021.08 (C3f). Obviously, since the signal m/z 2399.17 has been found to be an
instrumental artefact, its biological meaning is absolutely superimposed on that of the signal m/z
2021.08, and it will not be further discussed.
Our results show that the intensity of the two selected peptides was higher in the serum samples
from CRC patients than in those from healthy controls. Interestingly, while the difference for m/z
2021.08 was only found significant between healthy volunteers and metastatic CRC, the difference for
m/z 1561.72 was found significant between healthy volunteers and non-metastatic CRC too. Moreover,
since other authors described a dependence of complement levels on age and gender in the healthy
population [24], we confirmed our results for all three peptides by applying a multiple regression
model to adjust data by age and gender.
Cancer is a multifactorial disease whose onset is related to both genetic and environmental
factors. So, from the physio-pathological point of view, the increase of pro-thrombin fragment at m/z
1561.72 and full length C3f (m/z 2021.08) should be seen in a broader context taking into account
many other factors. Notwithstanding this premise, both the coagulation process and activation of the
complement system have been related, in the past, to carcinogenesis [25,26]. Pro-thrombin (factor II),
which is an essential component of the blood coagulation mechanism, is transformed into thrombin
by pro-thrombinase; then, thrombin transforms fibrinogen into fibrin, which, in combination with
platelets, forms the clot able to stop the bleeding. However, apart from the canonical task that it plays
in blood coagulation, thrombin has been shown to also affect the carcinogenesis process. Adams and
co-workers showed that pro-thrombin plays a broad role in the progression of colonic adenocarcinoma
that involves both promoting the growth of established tumours and the potential of circulating
tumour cells to form distant metastases [27]. Other authors established that the role of thrombin
in cancer pathogenesis is not limited to late events, such as metastasis. Thrombin can also strongly
influence the development of pre-cancerous lesions and subsequent tumour formation in the context
of inflammation-driven colon cancer [28]. With regard to other neoplasms, thrombin is one of the
main coagulation-related proteins increased in pancreatic cancer [29–31], while a signal of 4204 Da,
identified as a fragment of pro-thrombin by MALDI-TOF/TOF mass spectrometry, has been found
significantly increased in patients affected by biliary tract cancer [32].
Zain et al. found a concentration-dependent dual effect of thrombin on impaired growth/apoptosis
in tumour cells, mediated by the tumour cell PAR-1 thrombin receptor [33]. They demonstrated a clear
thrombin-enhanced tumour cell growth at relatively low thrombin concentration, but, at the same
time, that prolonged thrombin exposure leads to cell cycle arrest and apoptotic effect. Other studies
indicate that high thrombin concentrations are able to induce the caspases 1, 2 and 3, whose role
in programmed cell death has been described since the nineties [34]. In addition, clinical studies
suggested that anticoagulant treatments not only reduce cancer-related thromboembolic complications
but may also interfere with both cancer development and progression [35].
In the light of this evidence, it is not surprising that we found an increase in pro-thrombin derived
peptides in the serum of patients affected by colon cancer, in comparison with the healthy donors,
even with reference to non-metastatic patients.
The complement system is involved in the innate immunity and has an important function in
the surveillance against tumours [36], because it can be activated following the exposure to tumour
antigens [37]. During one of the last steps of the complement cascade, factors I and H cleave C3b into
Diagnostics 2020, 10, 1077 12 of 15
iC3b generating the 17 amino acids peptide C3f [38]. Notwithstanding, complement activation has
been considered for years a powerful tool for the elimination of cancer cells, a tumour-promoting role
has recently been proposed for this part of the immune system [39]. Indeed, complement activation
has been demonstrated to play a pro-tumorigenic role in inflammation-related colorectal cancer [40].
This observation is confirmed in the study carried out by Piao et al. where the authors describe the
role of the fraction C5a of the complement system on metastasis spreading by means of macrophages
stimulation [41]. This new point of view has convinced some researchers to hypothesize the concept of
blocking complement for the treatment of cancer [42]. Consistently with the study of Wang et al. [10],
we have identified the full length form of C3f fragment of the complement system (m/z 2021.08) as a
candidate biomarker for CRC. However, several authors have reported an increase of the C3f levels in
the biological fluids of patients affected by different cancer types [6,15,43,44].
Surprisingly, Bedin and co-workers described a lower intensity of the full length form of C3f fragment
in serum of patients affected by early and late CRC in comparison to the control group [45]. However,
this effect could be explained by the action of different N or/and C-terminal exopeptidases present in
the serum samples. Indeed, a characteristic degradation pattern has been described for many of the
proteins present in serum, including fibrinogen chains and complement components [13]. A confirmation
of this hypothesis comes from a previous study of the former authors [46] in which they described the
comparison of the plasma peptidome profile between healthy controls and patients affected by familial
adenomatous polyposis (FAP). They found a clear increase of the full-length form of the C3f fragment of
the complement system in FAP patients when compared with the healthy controls. However, they also
observed a different pattern in the spectra obtained from the analysis of plasma samples from patients
affected by colorectal cancer (CRC). In particular, they found a significant increase in signal m/z 1211.65
in CRC patients that is a degradation product of C3f. This observation leads us to suppose that the higher
concentration of the C3f full-length form in patients with FAP compared to CRC is likely to be the result
of a different peptidase activity, rather than a different complement system activation.
5. Conclusions
Though preliminary and obtained through a retrospective case-control study, our findings
showed that MALDI/TOF MS peptidomic analysis of serum may provide a novel approach to CRC
characterization. We observed that, while peptide C3f appears significantly increased only in serum
from metastatic CRC patients, the increase of the prothrombin fragment is already evident in the serum
of non-metastatic patients, suggesting its involvement in the early events of tumour progression.
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row reports the name of samples and the second row reports the group to which each sample belongs (1 for
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FAP familial adenomatous polyposis
FDR false discovery rate
fpA fibrinopeptide A
LMW low molecular weight
MS mass spectrometry
MS/MS tandem mass spectrometry
nano-HPLC-ESI nanoscale high-pressure liquid chromatography–electron spray ionization
SAM significant analysis of microarrays
SAMR implementation of SAM in the R language
SDQS SeraDeg quality score
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